Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Delivering purposeful solutions at Obesity Week 2025

October 9, 2025 | Obesity Week 

We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.

- PMLiVE

Obesity Week 2025 is the premier global event dedicated to obesity research, prevention, and care – bringing together leading scientists, clinicians, and innovators to advance progress in one of the most dynamic areas of healthcare.​

At Inizio, we’re uniting science, strategy, and creativity to deliver purposeful solutions across obesity and cardiometabolic health. Our integrated teams collaborate across the full commercialization journey to help clients navigate complexity, unlock value, and enhance outcomes at every stage of development and delivery.​

Our experience spans the full obesity ecosystem: we’ve supported over 20 leading anti-obesity therapies, partnered on 80% of the largest GLP-1 assets, and worked across 18 specialized services to deliver smarter, connected solutions that make an impact.​

Visit us at booth #812 to meet our experts and explore how Inizio’s integrated expertise is transforming the future of obesity and cardiometabolic care.​

If you’d like to meet with us at Obesity Week, please get in touch.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...

Webcast: AI in MRX: Harnessing the power of AI + people

Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.